Theragenics strengthens brachytherapy partnership with GE's Oncura
This article was originally published in Clinica
Prostate cancer treatment specialist Theragenics (Buford, Georgia) has strengthened its long-term partnership with GE Healthcare subsidiary Oncura by signing a new distribution agreement for the latter's OncoSeed brachytherapy product. Under the terms of the deal, Theragenics will distribute OncoSeed in North America on a non-exclusive basis for one year, 1 May. The agreement includes the options for additional one-year terms. OncoSeed is said to be the first seed used in prostate cancer treatments and widely considered to be the industry standard for iodine-125 based products, according to Theragenics.
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.